Evidence map›Paper›PMID 35859327›Full record

ArticleJournal of medical virology2022

Single-cell transcriptomic atlas reveals distinct immunological responses between COVID-19 vaccine and natural SARS-CoV-2 infection.

Yi Wang, Xiaoxia Wang, Laurence Don Wai Luu, Jieqiong Li, Xiaodai Cui, Hailan Yao, Shaojin Chen, Jin Fu, Licheng Wang, Chongzhen Wang and 8 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. A Large-Scale Single-Cell Atlas Reveals the Peripheral Immune Panorama of Bacterial Pneumonia.American journal of respiratory and critical care medicine · 2025
    Article
  9. T-cell exhaustion and antibody response in SARS-CoV-2 vaccine recipients.Revista peruana de medicina experimental y salud publica · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Yi WangExperimental Research Center, Capital Institute of Pediatrics, Beijing, P. R. China.ORCID 0000-0002-2031-087X
Xiaoxia WangCentral & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan, P. R. China.
Laurence Don Wai LuuSchool of Life Sciences, University of Technology Sydney, Sydney, Australia.
Jieqiong LiDepartment of Respiratory Disease, Beijing Pediatric Research Institute, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, P. R. China.
Xiaodai CuiExperimental Research Center, Capital Institute of Pediatrics, Beijing, P. R. China.
Hailan YaoDepartment of Biochemistry and Immunology, Capital Institute of Pediatrics, Beijing, P. R. China.
Shaojin ChenCentral & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan, P. R. China.
Jin FuExperimental Research Center, Capital Institute of Pediatrics, Beijing, P. R. China.
Licheng WangCentral & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan, P. R. China.
Chongzhen WangCentral & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan, P. R. China.
Rui YuanCentral & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan, P. R. China.
Qingguo CaiCentral & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan, P. R. China.
Xiaolan HuangExperimental Research Center, Capital Institute of Pediatrics, Beijing, P. R. China.
Junfei HuangLaboratory of Infectious Disease of Experimental Center, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, P. R. China.
Zhenjun LiState Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P.R. China.
Shijun LiLaboratory of Infectious Disease of Experimental Center, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, P. R. China.
Xiong ZhuCentral & Clinical Laboratory of Sanya People's Hospital, Sanya, Hainan, P. R. China.
Jun TaiDepartment of Otolaryngology, Head and Neck Surgery, Children's Hospital Capital Institute of Pediatrics, Beijing, P. R. China.
Sanya Central Hospital · CNCapital Institute of Pediatrics · CNGuizhou Center for Disease Control and Prevention · CNCapital Medical University · CNChildren's Hospital of Capital Institute of Pediatrics · CNNational Institute for Communicable Disease Control and Prevention · CNUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To control the ongoing coronavirus disease-2019 (COVID-19) pandemic, CoronaVac (Sinovac), an inactivated vaccine, has been granted emergency use authorization by many countries. However, the underlying mechanisms of the inactivated COVID-19 vaccine-induced immune response remain unclear, and little is known about its features compared to (Severe acute respiratory syndrome coronavirus 2) SARS-CoV-2 infection. Here, we implemented single-cell RNA sequencing (scRNA-seq) to profile longitudinally collected PBMCs (peripheral blood mononuclear cells) in six individuals immunized with CoronaVac and compared these to the profiles of COVID-19 infected patients from a Single Cell Consortium. Both inactivated vaccines and SARS-CoV-2 infection altered the proportion of different immune cell types, caused B cell activation and differentiation, and induced the expression of genes associated with antibody production in the plasma. The inactivated vaccine and SARS-COV-2 infection also caused alterations in peripheral immune activity such as interferon response, inflammatory cytokine expression, innate immune cell apoptosis and migration, effector T cell exhaustion and cytotoxicity, however, the magnitude of change was greater in COVID-19 patients, especially those with severe disease, than in immunized individuals. Further analyses revealed a distinct peripheral immune cell phenotype associated with CoronaVac immunization (HLA class II upregulation and IL21R upregulation in naïve B cells) versus SARS-CoV-2 infection (HLA class II downregulation and IL21R downregulation in naïve B cells from severe disease individuals). There were also differences in the expression of important genes associated with proinflammatory cytokines and thrombosis. In conclusion, this study provides a single-cell atlas of the systemic immune response to CoronaVac immunization and revealed distinct immune responses between inactivated vaccines and SARS-CoV-2 infection.

Indexed as

COVID-19Viral VaccinesAntibodies, ViralCOVID-19 VaccinesCytokinesHumansLeukocytes, MononuclearReceptors, Interleukin-21SARS-CoV-2TranscriptomeVaccines, InactivatedAntibodies, ViralCOVID-19 VaccinesCytokinesReceptors, Interleukin-21Vaccines, InactivatedViral VaccinesCoronaVacCOVID-19immunological responsesinactivated vaccineSARS-CoV-2single-cell sequencing

Identifiers

PMID35859327
PMCPMC9350186
OpenAlexW4286208609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.